[
    {
        "file_name": "PREMIERBIOMEDICALINC_05_14_2020-EX-10.2-INTELLECTUALPROPERTYAGREEMENT.txt",
        "perturbation": [
            {
                "type": "Omissions - In Text Contradiction",
                "original_text": "WHEREAS, Marv has subsequently filed numerous patent applications on subject matter related to the Issued Patents which are listed in Appendix A. WHEREAS, Marv and Premier expanded Premier's Exclusive License to include all the Applications listed in Appendix A via a Third Addendum to the 2010 Agreement executed by Marv and Premier on the Effective Date (\"2020 Agreement\"). WHEREAS, Marv has filed US provisional patent applications specifically related to methods of treatment for Covid-19 as starred in Appendix A (Covid-19 Applications) to which Premier has an exclusive license via the 2020 Agreement.",
                "changed_text": "WHEREAS, Marv has subsequently filed numerous patent applications on subject matter related to the Issued Patents. WHEREAS, Marv and Premier expanded Premier's Exclusive License via a Third Addendum to the 2010 Agreement executed by Marv and Premier on the Effective Date (\"2020 Agreement\"). WHEREAS, Marv has filed US provisional patent applications specifically related to methods of treatment for Covid-19 (Covid-19 Applications) to which Premier has an exclusive license via the 2020 Agreement.",
                "explanation": "By removing the reference to 'Appendix A' in several 'WHEREAS' clauses, the contract now has internal contradictions. Later sections reference the Applications listed in Appendix A but it is never defined.",
                "location": "RECITALS"
            },
            {
                "type": "Omissions - In Text Contradiction",
                "original_text": "2.      LICENSING. To the extent that terms in the 2010 Agreement/2020 Agreement are not contradicted or revised here, the terms as stated in 2010 Agreement/2020 Agreement remain in full effect, are controlling, and apply to THI licensing of the Applications in Appendix A and the Licensed Products derived therefrom.",
                "changed_text": "2.      LICENSING. To the extent that terms in the 2010 Agreement/2020 Agreement are not contradicted or revised here, the terms as stated in 2010 Agreement/2020 Agreement remain in full effect, are controlling, and apply to THI licensing of the Licensed Products derived therefrom.",
                "explanation": "The removal of 'the Applications in Appendix A' creates ambiguity. The licensing applies to Licensed Products, but if there is no applications listed, then enforcement is affected.",
                "location": "Section 2"
            },
            {
                "type": "Omissions - In Text Contradiction",
                "original_text": "THI shall prepay Marv for any affirmed IP Cost before payment is to be made by Marv. Marv shall have no duty to pay an IP Cost, whether affirmed or not affirmed, for which Marv does not receive prepayment. If THI does not pay Marv by the Due Date, the Application or Patent shall revert to Marv as if THI had denied payment under section 2(c)3.",
                "changed_text": "THI shall prepay Marv for any affirmed IP Cost before payment is to be made by Marv. Marv shall have no duty to pay an IP Cost, whether affirmed or not affirmed, for which Marv does not receive prepayment. If THI does not pay Marv by the Due Date, the Patent shall revert to Marv as if THI had denied payment under section 2(c)3.",
                "explanation": "By removing the word 'Application' creates ambiguity. If only the Patent reverts, what happens to the Application? Does THI still have a license to the Application?",
                "location": "Section 2(c)4"
            }
        ]
    }
]